ABBOTT PARK, Ill., Nov. 6, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA® ...

MONTREAL, Feb. 20, 2019 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA® (adalimumab) for the treatment of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In 2021, Humira — the blockbuster biologic that has for ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The first Humira biosimilar hit the U.S. market a little ...

WASHINGTON, Aug 28 (Reuters) - Abbott Laboratories Inc won a U.S. panel's support o n T uesday for wider use of its blockbuster rheumatoid arthritis drug, Humira, for treating a type of inflammatory ...

NEW YORK, Oct 21 (Reuters) - Sales of Humira, the arthritis drug Abbott Laboratories Inc is spinning off as the cornerstone of another company, will grow by $1 billion a year for the foreseeable ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

One of the most popular prescription medications in the world is about to face fierce competition in the U.S. — something that could mean lower prices for the drug but a difficult coming year for the ...

North Chicago-based drugmaker AbbVie must pay back Medicare for raising the price of its blockbuster drug Humira too quickly, the federal government said Wednesday. The penalty follows years of ...